Acorah Software Products - Accounts Production 15.0.500 false true 30 November 2022 1 November 2021 false 1 December 2022 30 November 2023 30 November 2023 10103359 Mrs Divya Patel Mr Harshad Patel Mr Mitul Patel iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 10103359 2022-11-30 10103359 2023-11-30 10103359 2022-12-01 2023-11-30 10103359 frs-core:ShareCapital 2023-11-30 10103359 frs-core:RetainedEarningsAccumulatedLosses 2023-11-30 10103359 frs-bus:PrivateLimitedCompanyLtd 2022-12-01 2023-11-30 10103359 frs-bus:FilletedAccounts 2022-12-01 2023-11-30 10103359 frs-bus:SmallEntities 2022-12-01 2023-11-30 10103359 frs-bus:AuditExempt-NoAccountantsReport 2022-12-01 2023-11-30 10103359 frs-bus:SmallCompaniesRegimeForAccounts 2022-12-01 2023-11-30 10103359 frs-core:CostValuation 2022-11-30 10103359 frs-core:CostValuation 2023-11-30 10103359 frs-core:ProvisionsForImpairmentInvestments 2022-11-30 10103359 frs-core:ProvisionsForImpairmentInvestments 2023-11-30 10103359 frs-bus:Director1 2022-12-01 2023-11-30 10103359 frs-bus:Director2 2022-12-01 2023-11-30 10103359 frs-bus:Director3 2022-12-01 2023-11-30 10103359 frs-countries:EnglandWales 2022-12-01 2023-11-30 10103359 2021-10-31 10103359 2022-11-30 10103359 2021-11-01 2022-11-30 10103359 frs-core:CurrentFinancialInstruments 2022-11-30 10103359 frs-core:ShareCapital 2022-11-30 10103359 frs-core:RetainedEarningsAccumulatedLosses 2022-11-30
Registered number: 10103359
Pharmaco (Merseyside) Limited
Unaudited Financial Statements
For The Year Ended 30 November 2023
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 10103359
30 November 2023 30 November 2022
Notes £ £ £ £
FIXED ASSETS
Investments 4 2,248,796 2,248,796
2,248,796 2,248,796
CURRENT ASSETS
Debtors 5 3,326 4,500
3,326 4,500
Creditors: Amounts Falling Due Within One Year 6 - (238,790 )
NET CURRENT ASSETS (LIABILITIES) 3,326 (234,290 )
TOTAL ASSETS LESS CURRENT LIABILITIES 2,252,122 2,014,506
NET ASSETS 2,252,122 2,014,506
CAPITAL AND RESERVES
Called up share capital 1,250 1,250
Profit and Loss Account 2,250,872 2,013,256
SHAREHOLDERS' FUNDS 2,252,122 2,014,506
Page 1
Page 2
For the year ending 30 November 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Harshad Patel
Director
30 July 2024
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Pharmaco (Merseyside) Limited is a private company, limited by shares, incorporated in England & Wales, registered number 10103359 . The registered office is 205 Plumstead Road, Norwich, Norfolk, NR1 4AB.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 3 (2022: 3)
3 3
4. Investments
Subsidiaries
£
Cost
As at 1 December 2022 2,248,796
As at 30 November 2023 2,248,796
Provision
As at 1 December 2022 -
As at 30 November 2023 -
Net Book Value
As at 30 November 2023 2,248,796
As at 1 December 2022 2,248,796
Details of investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:
Undertaking                                           Holding                         Proporation of voting rights &shares
Subsidiary undertakings
Paxton Limited                                       Ordinary shares           100%
Registered office
205 Plumstead Road, Norwich, Norfolk, United Kingdom, NR1 4AB
The principal activity of Paxton Limited is supply medicines and other goods as a pharmacy.
The profit for the financial period of Paxton Limited was £252,271 and the aggregate amount of capital and reserves  at the end of the period was £44,790.
5. Debtors
30 November 2023 30 November 2022
£ £
Due within one year
Other debtors 3,326 4,500
Page 3
Page 4
6. Creditors: Amounts Falling Due Within One Year
30 November 2023 30 November 2022
£ £
Amounts owed to group undertakings - 238,790
7. Related Party Transactions
Mr Harshad Patel, Mrs Divya Patel and Mr Mitul Patel are directors of the company. At the end of the year amount owed by the company to the directors is £0.00 (2022: £0.00).
During the year, the company has declared dividend of £0.00 (2022: £0.00).
8. Summary of transactions with subsidiaries
Summary of transactions with subsidiaries
Paxton Limited
(100% subsidiary undertaking of the Pharmaco (Merseyside) Limited)
Paxton Limited has given a cross guarantee towards the company's bank borrowings supported by a debenture created on 8 August 2019 and a legal charge over the leasehold property Paxton Limited trades from.
At the balance sheet date the amount Owed by Paxton Limited was £0.00 ( 2022 :£238,790 ). The loan is interest free and repayable on demand.
Page 4